mRNA Vaccine for Pancreatic Cancer: Promising Trial Results and Hope for Patients

Personalized mRNA vaccines for pancreatic cancer continue to show promise in early clinical trials, with recent follow-up data indicating that patients who mounted an immune response to the vaccine experienced significantly improved long-term survival compared to historical averages for the disease.

In a phase 1 trial conducted by Memorial Sloan Kettering Cancer Center, 16 patients with surgically removable pancreatic tumors received an individualized therapeutic mRNA vaccine called autogene cevumeran (BNT122, RO7198457) following surgery, chemotherapy, and treatment with an immunotherapy checkpoint inhibitor. The vaccine was custom-made for each patient based on the unique genetic changes in their tumor DNA.

Of the 16 patients enrolled, eight demonstrated a successful immune response to the vaccine, as measured by the activation of tumor-targeting T cells. Among those eight responders, seven were still alive six years after the trial began — a notable outcome for a cancer type with a typical five-year survival rate of approximately 13 percent, according to the American Cancer Society’s Cancer Statistics 2026 report.

Follow-up results presented at the 2026 Annual Meeting of the American Association for Cancer Research showed that nearly 90 percent of patients whose immune systems responded to the vaccine remained alive up to six years after receiving the last treatment. These findings suggest the vaccine may help stimulate a durable immune response capable of delaying or preventing cancer recurrence in a subset of patients.

The research team, led by physician-scientist Vinod Balachandran, MD, Director of the Olayan Center for Cancer Vaccines at Memorial Sloan Kettering, emphasized that detecting and tracking vaccine-activated T cells was a crucial part of the study. This effort was co-led by computational biologist Benjamin Greenbaum, PhD, Co-Director of the Olayan Center for Cancer Vaccines.

Autogene cevumeran is being developed and researched by BioNTech and Genentech, a member of the Roche Group. While the phase 1 trial primarily assessed safety and immune response, the observed correlation between immune activation and prolonged survival has supported plans for larger validation studies.

Experts caution that pancreatic cancer remains one of the most lethal common cancers, with limited effective treatments and high recurrence rates even after surgery. Larger trials will be needed before personalized mRNA vaccines like autogene cevumeran can be considered a standard treatment option.

The investigational approach reflects a broader effort to use mRNA technology — best known for its role in infectious disease vaccines — to train the immune system to recognize and attack cancer-specific targets. Early clinical and preclinical results across multiple studies have shown that such vaccines can induce tumor-targeting immune responses in patients with pancreatic cancer, correlating with delayed recurrence or prolonged survival in small patient groups.